DDInter998 DDInter233
Ivermectin is a semi-synthetic antiparasitic medication derived from avermectins, a class of highly-active broad-spectrum antiparasitic agents isolated from the fermentation products of _Streptomyces avermitilis_. Ivermectin itself is a mixture of two avermectins, comprising roughly 90% 5-O-demethyl-22,23-dihydroavermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1a</sub>) and 10% 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro­-25-(1-methylethyl)avermectin A<sub>1a</sub> (22,23-dihydroavermectin B<sub>1b</sub>). Ivermectin is mainly used in humans in the
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Ivermectin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Ivermectin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nefazodone
Nefazodone {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Ivermectin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) POLD4
POLD4 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) POLD4
POLD4 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) TRIB1
TRIB1 {u} (Gene) is downregulated by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Ivermectin {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Ivermectin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ivermectin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound) and Nefazodone may lead to a major life threatening interaction when taken with Brigatinib
Ivermectin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ivermectin (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Ivermectin (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Brigatinib
Ivermectin (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Ivermectin (Compound) upregulates TRIB1 (Gene) and TRIB1 (Gene) is downregulated by Levonorgestrel (Compound) and Levonorgestrel may lead to a major life threatening interaction when taken with Brigatinib
Ivermectin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib